SparingVision raises €44.5m for retinitis pigmentosa gene therapyFrench biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare Share XSparingVision raises €44.5m for retinitis pigmentosa gene therapyhttps://pharmaphorum.com/news/sparingvision-raises-44-5-million-euros-for-retinitis-pigmentosa-gene-therapy/
US snaps up first supplies of Regeneron’s COVID-19 antibodyHard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has Share XUS snaps up first supplies of Regeneron’s COVID-19 antibodyhttps://pharmaphorum.com/news/us-snaps-up-first-supplies-of-regenerons-covid-19-antibody/
Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&DCalifornia biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last Share XPoseida Therapeutics aims for $115m stock market launch to fund CAR-T R&Dhttps://pharmaphorum.com/news/poseida-therapeutics/
NodThera raises $55m in Series B round to trial inflammatory disease drugsThe Anglo-US biotech NodThera has raised $55 million in a second financing round as it prepares its inflammatory Share XNodThera raises $55m in Series B round to trial inflammatory disease drugshttps://pharmaphorum.com/news/nodthera-raises/
AI drug discovery firm Exscientia gets $60M cash injectionUK artificial intelligence specialist Exscientia has topped up its coffers with a $60 million Series C funding round Share XAI drug discovery firm Exscientia gets $60M cash injectionhttps://pharmaphorum.com/news/ai-drug-discovery-firm-exscientia-gets-60m-cash-injection/
US government gives Moderna $483m for COVID-19 vaccineThe US government has agreed to provide a whopping $483 million in federal funding to propel Modera’s coronavirus Share XUS government gives Moderna $483m for COVID-19 vaccinehttps://pharmaphorum.com/news/us-government-gives-modernas-covid-19-vaccine-483m-backing/
Cancer Research UK cuts research funding as COVID-19 hits incomeCancer Research UK has cut funding to its research activities, as the charity faces a cut to its Share XCancer Research UK cuts research funding as COVID-19 hits incomehttps://pharmaphorum.com/news/cancer-research-uk-cuts-funding-as-covid-19-hits-income/
Call for mandatory disclosure of industry funding of patient groupsExperts have warned that few patient groups have formal policies governing corporate funding and financial transparency, despite widespread Share XCall for mandatory disclosure of industry funding of patient groupshttps://pharmaphorum.com/news/call-for-mandatory-disclosure-of-industry-funding-of-patient-groups/
Digital health M&A bounces back in Q2Mergers and acquisitions in digital health bounced back strongly in Q2 after almost grinding to a halt at Share XDigital health M&A bounces back in Q2https://pharmaphorum.com/news/digital-health-ma-bounces-back-in-q2/
